Intrinsic Pathway The intrinsic pathway is one of two initiating pathways of the coagulation cascade (the other is the extrinsic pathway, initiated by tissue factor). Factor XII activates Factor XI, which activates Factor IX. Factor IX then combines with its cofactor Factor VIII to activate Factor X—the common pathway where all coagulation pathways converge. Deficiency of either Factor VIII (in hemophilia A) or Factor IX (in hemophilia B) impairs this pathway's function.

Factor VIII This glycoprotein acts as a cofactor for Factor IX, dramatically accelerating the activation of Factor X. Without Factor VIII, the intrinsic pathway functions at only a fraction of normal capacity. Factor VIII is produced in the liver and endothelial cells.

Factor IX This vitamin K-dependent protease is produced in the liver. It requires activation by Factor XIa to function in the cascade. Deficiency impairs the intrinsic pathway similarly to Factor VIII deficiency.

Joints (Target of Damage) The knees, elbows, and ankles are most commonly affected by hemarthrosis. Synovial lining of joints is highly vascular and susceptible to bleeding. Repeated bleeds cause inflammation, cartilage destruction, and chronic arthritis.

Muscles Muscle hematomas (bleeds into muscle tissue) are common, particularly in large muscle groups like quadriceps, iliopsoas, and calf muscles. These can cause compartment syndrome and nerve compression.

Central Nervous System Intracranial hemorrhage is the most serious bleeding manifestation and a leading cause of mortality in hemophilia. Any head trauma in a person with hemophilia requires immediate evaluation.

Hemophilia A Caused by deficiency or dysfunction of Factor VIII. Accounts for approximately 80% of all hemophilia cases. Further classified by severity as severe, moderate, or mild based on residual Factor VIII activity.

Hemophilia B Caused by deficiency of Factor IX. Also called Christmas disease, named after the first patient described with this condition in 1952. Similar clinical presentation to hemophilia A but generally considered slightly milder.

Severe Hemophilia Factor activity less than 1% of normal. Spontaneous bleeding episodes occur without obvious trigger. Presents in early infancy or childhood. Typically requires prophylactic (preventive) factor replacement.

Moderate Hemophilia Factor activity between 1-5% of normal. Bleeding occurs with minor trauma. May have occasional spontaneous bleeds. Treatment is typically on-demand.

Mild Hemophilia Factor activity between 5-40% of normal. Bleeding only with significant trauma, surgery, or dental procedures. May not be diagnosed until adulthood. Often responds to desmopressin.

Acquired Hemophilia Rare autoimmune condition where the body develops antibodies (inhibitors) against Factor VIII. Typically occurs in older adults, often associated with pregnancy, malignancy, or autoimmune disease. Different from congenital hemophilia.

Hemophilia with Inhibitors Some patients with congenital hemophilia develop inhibitors—antibodies that neutralize infused Factor VIII or IX, making treatment very challenging. This occurs in approximately 30% of severe hemophilia A patients and 5% of hemophilia B patients.

X-Linked Recessive Inheritance The genes for Factor VIII (F8) and Factor IX (F9) are located on the X chromosome. Males have XY chromosomes—affected males have the defective gene on their single X chromosome. Females have XX chromosomes—a female with one defective X chromosome is a carrier and typically has mild or no symptoms, though some carriers have sufficiently low factor levels to have bleeding symptoms.

Spontaneous Mutations Approximately 30% of hemophilia cases occur in families without prior history—the affected individual has a spontaneous mutation in the F8 or F9 gene. These new mutations can then be passed to future generations.

Specific Gene Mutations Over 2,000 different mutations in the F8 and F9 genes have been identified causing hemophilia. Some mutations correlate with severity and inhibitor risk. Large intron 22 inversion is the most common mutation in severe hemophilia A.

Genetic Factors Certain F8 gene mutations (particularly null mutations producing no protein) increase inhibitor risk. Family history of inhibitors increases risk.

Environmental Factors Intensive factor exposure (particularly in first 50 exposure days), surgery, and breakthrough bleeds on prophylaxis may increase inhibitor risk.

Gender Males are almost exclusively affected. Female carriers may have symptoms.

Age Severe hemophilia presents in early childhood. Mild hemophilia may be diagnosed at any age.

Family History Known family history increases risk, though many cases arise from new mutations.

Hemophilia occurs across all ethnic groups with relatively similar prevalence. The high rate of consanguineous marriage in some populations may increase prevalence of inherited bleeding disorders.

At Healers Clinic Dubai, we care for patients with both hemophilia A and B, including those with severe disease and inhibitors. The availability of recombinant factor products and specialized hemophilia treatment centers has improved care significantly in the region.

Spontaneous Bleeding In severe hemophilia, bleeding occurs without any known trigger. Common sites include joints, muscles, and mucous membranes. The frequency varies between individuals.

Post-Traumatic Bleeding Bleeding after injury is prolonged and may continue longer than expected. Even minor injuries can cause significant blood loss.

Surgical/Dental Bleeding Procedures that would cause minor bleeding in normal individuals can cause severe, prolonged bleeding in hemophilia patients. Pre-procedure factor coverage is essential.

Joints (Hemarthrosis) Most common site of serious bleeding. Knees, elbows, and ankles most frequently affected. Acute hemarthrosis causes pain, swelling, warmth, and limited range of motion. Repeated bleeds cause chronic joint damage.

Muscles (Hematomas) Common in large muscles—quadriceps, iliopsoas, calves, forearms. Can cause compartment syndrome and nerve damage. Iliopsoas hematoma can be confused with appendicitis.

Mucous Membranes Nosebleeds, gum bleeding, and blood in urine or stool are common.

Skin Easy bruising, ecchymoses (large bruises), and prolonged bleeding from cuts.

Intracranial Most serious—head trauma in hemophilia requires immediate factor coverage and evaluation.

Hemarthropathy Chronic arthritis from repeated joint bleeds. Causes pain, stiffness, reduced range of motion, and functional impairment. The leading cause of disability in hemophilia.

Inhibitor Development Antibodies that neutralize infused factor, making treatment extremely difficult. Requires specialized management with bypassing agents.

Transfusion-Related Complications Before recombinant factors were available, factor concentrates carried risk of HIV, hepatitis, and other blood-borne infections. Modern recombinant products have eliminated this risk.

Step 1: Detailed History We gather comprehensive information including personal and family bleeding history, age at first bleeding episode, frequency and sites of bleeding, history of joint problems, inhibitor history, and current treatment regimen.

Step 2: Physical Examination We assess for signs of bleeding—bruises, joint swelling, limited range of motion—and examine joints commonly affected by hemarthrosis.

Step 3: Constitutional Assessment Our integrative approach includes homeopathic case-taking (Service 3.1), Ayurvedic assessment (Service 1.6), and NLS Screening (Service 2.1) to understand the individual's constitutional picture and guide personalized treatment.

Coagulation Studies Prothrombin time (PT) is normal. Activated partial thromboplastin time (aPTT) is prolonged. The mixing study (patient plasma mixed with normal plasma) corrects the aPTT in hemophilia but not in lupus anticoagulant.

Factor Assays Specific measurement of Factor VIII or IX activity determines hemophilia type and severity.

Inhibitor Testing The Nijmegen Bethesda assay detects neutralizing antibodies (inhibitors) that can complicate treatment.

Genetic Testing Can identify specific mutations in F8 or F9 genes. Useful for prenatal diagnosis, carrier testing in families, and predicting inhibitor risk.

von Willebrand Disease The most common inherited bleeding disorder. Affects both males and females. Causes prolonged bleeding due to deficiency of von Willebrand factor, which carries Factor VIII and aids platelet function.

Other Factor Deficiencies Rare deficiencies of other clotting factors (VII, X, XI, XIII) can cause bleeding but have different patterns.

Acquired Bleeding Disorders Liver disease, vitamin K deficiency, and disseminated intravascular coagulation can cause bleeding but have different laboratory findings.

On-Demand Treatment Infusing clotting factor when bleeding occurs. Used for mild/moderate hemophilia and for severe hemophilia when prophylaxis is not used.

Prophylaxis Regular (usually 2-3 times per week) infusions of factor to prevent bleeding episodes. Standard of care for severe hemophilia, especially in children. Dramatically reduces joint damage.

Recombinant Factors Genetically engineered factor products—now standard of care. No risk of blood-borne infections. Available for both Factor VIII and IX.

Desmopressin (DDAVP) Releases stored Factor VIII from endothelial cells. Effective in mild hemophilia A. Contraindicated in severe hemophilia and some cardiovascular conditions.

Antifibrinolytic Agents Tranexamic acid or aminocaproic acid help stabilize clots. Particularly useful for mucosal bleeding (nosebleeds, dental work).

Emerging Curative Treatment Gene therapy involves delivering a functional copy of the F8 or F9 gene to the patient's liver cells, enabling them to produce normal clotting factor. Several products have shown promising results in clinical trials and are approaching FDA approval. Offers potential cure but long-term durability unknown.

Immune Tolerance Induction (ITI) Intensive factor infusions to eliminate inhibitors. Very expensive and time-consuming (months to years).

Bypassing Agents Recombinant Factor VIIa or activated prothrombin complex concentrates used when inhibitors prevent factor replacement.

Constitutional homeopathy supports overall well-being in individuals with hemophilia. While it cannot replace factor replacement, remedies are selected based on complete symptom picture.

Key Homeopathic Remedies:

In Ayurveda, hemophilia relates to rakta dhatu (blood tissue) imbalance and Pitta/Vata disturbance. Treatment focuses on supporting blood tissue and calming bleeding tendencies.

Ayurvedic Treatment Approaches:

• Pitta-pacifying diet
• Blood-supporting herbs (manjistha, ashoka, lodhra)
• Cooling preparations
• Gentle lifestyle modifications

Nutritional support optimizes overall health and may support coagulation:

Dietary Recommendations:

• Adequate vitamin K for clotting factor production (leafy greens)
• Iron-rich foods if anemic (from chronic blood loss)
• Vitamin C for tissue health
• Avoid aspirin and NSAIDs that impair platelet function

Avoid Trauma Use protective gear for sports. Avoid contact sports with high injury risk. Use caution with sharp objects.

Safe Environment Pad corners and sharp edges in home. Use electric razors. Wear medical alert identification.

RICE Protocol Rest, Ice, Compression, Elevation for muscle hematomas and joint bleeds.

Early Factor Infusion Infuse factor as directed by your hemophilia treatment center at first sign of significant bleeding.

Avoid Certain Medications Aspirin and NSAIDs (ibuprofen, naproxen) impair platelet function and should be avoided.

Genetic Counseling For families with hemophilia, genetic counseling helps understand inheritance patterns and reproductive options.

Prenatal Diagnosis Chorionic villus sampling (10-12 weeks) or amniocentesis (15-18 weeks) can determine if a fetus has hemophilia.

Newborn Testing If hemophilia is suspected, testing can be performed shortly after birth.

Life Expectancy With modern factor replacement therapy, individuals with hemophilia can expect near-normal life expectancy.

Quality of Life Prophylaxis has dramatically improved quality of life, allowing children to attend school regularly and adults to work and exercise.

Joint Disease The major long-term complication is hemarthropathy from repeated joint bleeds. Modern prophylaxis has substantially reduced this complication.

Inhibitors Inhibitor development remains a significant challenge but can often be managed with specialized treatments.

Q: Can hemophilia be cured? A: Gene therapy offers the potential for cure and is showing promising results in clinical trials. For now, hemophilia is managed with factor replacement therapy, but a functional cure may be available soon.

Q: Can females have hemophilia? A: Hemophilia is extremely rare in females because it requires inheriting defective genes from both parents. Females are typically carriers and may have mild bleeding symptoms.

Q: What is the difference between hemophilia A and B? A: The only difference is which clotting factor is deficient—Factor VIII in A, Factor IX in B. The bleeding patterns and treatment are very similar.

Q: Is hemophilia always inherited? A: About 30% of cases result from spontaneous mutations with no family history. These can then be passed to future generations.

Q: Can people with hemophilia have normal lives? A: Yes—modern treatment allows most people with hemophilia to lead full, active lives. With prophylactic treatment, children can attend school and participate in many activities.

Q: What are the warning signs of internal bleeding in hemophilia? A: Warning signs include severe headache, neck stiffness, confusion (possible brain bleed), joint pain and swelling (especially knees, elbows, ankles), muscle pain and firmness, inability to move a limb, abdominal pain, blood in urine or stool, and prolonged bleeding from any wound. Seek immediate medical attention for these symptoms.

Q: How is hemophilia diagnosed? A: Diagnosis involves blood tests to measure clotting factor levels. Factor VIII deficiency indicates hemophilia A, while factor IX deficiency indicates hemophilia B. Severity is classified based on factor levels: mild (5-40% of normal), moderate (1-5%), or severe (<1%). Genetic testing can identify the specific gene mutation and is useful for family planning.

Q: What is prophylaxis treatment? A: Prophylaxis involves regular factor infusions to prevent bleeding episodes rather than treating them after they occur. This is the standard of care for severe hemophilia, especially in children, and helps prevent joint damage and other complications.

Q: What are inhibitors and how are they treated? A: Inhibitors are antibodies that neutralize factor replacement, making treatment ineffective. About 20-30% of severe hemophilia A patients develop inhibitors. Treatment includes immune tolerance induction (ITI) therapy, bypassing agents (FEIBA, rFVIIa), and newer therapies like emicizumab.

Q: What activities are safe for people with hemophilia? A: Low-impact activities are generally safe and encouraged, including swimming, walking, yoga, cycling, and dancing. Contact sports and high-risk activities should be avoided. Each person should discuss appropriate activities with their hematologist based on their severity and factor levels.

Q: How does hemophilia affect dental care? A: Dental procedures can cause significant bleeding in hemophilia. Special precautions include factor coverage before procedures, use of antifibrinolytic medications (tranexamic acid), and coordination between dentist and hematologist. Regular dental care is important to prevent problems that might require procedures.

Q: What is gene therapy for hemophilia? A: Gene therapy aims to provide a functional copy of the defective gene, potentially allowing the body to produce its own clotting factor. Several gene therapies have shown promising results in clinical trials and are now approved for some patients. This treatment offers the possibility of long-term or permanent reduction in bleeding episodes.

Q: How does homeopathy support patients with hemophilia? A: Classical homeopathy provides constitutional support and may help with overall wellbeing, energy levels, and recovery from bleeding episodes. Individualized remedies are selected based on the complete symptom picture. Homeopathy is used as a complementary therapy alongside conventional factor replacement treatment.

Q: What should I carry as emergency identification? A: People with severe hemophilia should carry medical identification (bracelet or card) indicating their diagnosis, severity, factor deficiencies, inhibitor status, and treatment center contact information. This ensures appropriate care in emergency situations.